TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03704025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile device guided rehabilitation
Description: Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. Study group will have virtual glasses or mobile device to motivate and control exercise training program.
Study: NCT03130400

Intervention type: PROCEDURE
Intervention: Observational gait analysis procedure
Description: All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
Study: NCT00404547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Asthma Care with Alvesco

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Inhaled Glucocorticosteroids
Description: Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
Study: NCT04117906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAGE training for anxiety
Description: STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
Study: NCT04130373

Intervention type: PROCEDURE
Intervention: Autologous fat grafting procedure
Description: Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.

Intervention type: PROCEDURE
Intervention: Breast reconstruction
Description: Breast reconstructive procedures after oncological radical or conservative breast surgery

Intervention type: PROCEDURE
Intervention: Breast reconstruction
Description: Breast reconstructive procedures after oncological radical or conservative breast surgery
Study: NCT03892122

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol Fresenius
Description: Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration- and depth of anesthesia-as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
Study: NCT01243398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT04455412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Assisted ICSI
Description: using OCTICS laser device to do small opening or zona thinning to improve ICSI outcome

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Assisted ICSI
Description: using OCTICS laser device to do small opening or zona thinning to improve ICSI outcome
Study: NCT01188330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WITH Comprehensive Geriatric assessment
Description: Each month after randomization, a nurse practitioner will systematically review the intervention plan.~In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: no Comprehensive Geriatric assessment
Study: NCT00833105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES treatment
Description: The AMES device rotates the fingers-thumb or the wrist in the flexion-extension directions over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that are lengthened by the thumb-finger or hand movement. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
Study: NCT01668173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
Study: NCT03864679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will perform a cycling test with 5 min incremental intensity exercise and 1 h cycling test exercising at a moderate-intensity (load will be selected in incremental intensity exercise).
Study: NCT03759587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib capsule
Study: NCT02737930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02497560

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: proprietary formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: proprietary formula

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: proprietary formula
Study: NCT02166060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 5 mg twice a day or 7,5 mg twice a day
Study: NCT03397706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRx-3996
Description: Taken orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRx-3996
Description: Taken orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRx-3996
Description: Taken orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Taken orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Taken orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Taken orally once or twice daily
Study: NCT03726125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3374849 - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3374849 - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3374849 - IV
Description: Administered IV
Study: NCT00022698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT03726125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3374849 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec - IV
Description: Administered IV
Study: NCT04960436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscus Allograft Transplantation
Description: patients received surgery of Meniscus Allograft Transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meniscectomy
Description: patients received surgery of Meniscectomy
Study: NCT04147091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ApaCare & Repair
Description: Initial cariuos lesions were treated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ApaCare & Repair
Description: Initial cariuos lesions were treated.
Study: NCT00022698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT04147091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ApaCare & Repair
Description: Initial cariuos lesions were treated.
Study: NCT04171258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: Active Comparator
Study: NCT01861652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Health Systems Vasculaire Leg Compression Device
Description: Leg (calf) compression device used to alleviate symptoms of restless legs
Study: NCT01762436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bisoprolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol
Study: NCT00550745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live
Description: single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: single 0.65 mL Placebo injection. 6 month treatment period.
Study: NCT03130400

Intervention type: PROCEDURE
Intervention: Observational gait analysis procedure
Description: All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;

Intervention type: PROCEDURE
Intervention: Observational gait analysis procedure
Description: All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
Study: NCT00879476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril 10mg capsules
Study: NCT02425566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
Study: NCT01864551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study: NCT00607074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)
Description: Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Giardia treatment only (secnidazole or albendazole)
Description: Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group (placebo)
Description: Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
Study: NCT00078767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: 12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Pill
Description: 12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline Pill
Description: 12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
Study: NCT04076293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15912
Description: The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
Study: NCT02644993

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Study: NCT02088905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy
Description: Parent-Child Interaction Therapy (PCIT) is a research-supported parent coaching intervention that has been found to be highly effective among typically developing preschoolers presenting with a range of mental health concerns, especially defiance and noncompliance.6 PCIT holds considerable promise as a potentially effective treatment for children with ASD because it directly addresses the behaviors parents of children with ASD report to be most problematic for them - defiance, stubbornness, and temper tantrums. PCIT is theoretically consistent with other approaches that have shown promise in treating ASD (i.e., behaviorally-based); however, PCIT is unique in that it incorporates a socially-based initial phase which may have some unique benefits for children with ASD.
Study: NCT00291876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: 2 doses at 12 months interval
Study: NCT03348007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking two kinds of mineral water
Description: 1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taking two kinds of mineral water
Description: 1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).
Study: NCT00940823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed FP7 Valve
Description: Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt-350 Tube
Description: Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
Study: NCT03395145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal
Description: Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation after tooth extraction
Study: NCT04527289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine (100mg) as add on therapy.
Description: Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will be managed with placebo as add on to the standard regimen.
Study: NCT01377350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumedicares monitoring system.
Description: 50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumedicares monitoring system
Description: Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
Study: NCT02763137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard LD/CD
Description: LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
Study: NCT01099904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: multiple oral doses for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: multiple oral doses for 5 days
Study: NCT02763137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semi continuous intra-oral administration of LD/CD
Description: Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
Study: NCT02158013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Levorag Emulgel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Study: NCT01099904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: multiple oral doses for 5 days
Study: NCT03986112

Intervention type: BIOLOGICAL
Intervention: carotid sonography and inferior vena cava sonography
Description: Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
Study: NCT02119416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration first
Description: All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Caffeine Administration first (1mg/kg body weight)
Description: On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Caffeine Administration first (2mg/kg body weight)
Description: On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
Study: NCT02363556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol administered vaginally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol administered buccally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol administered vaginally with Dilapan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol administered buccally with Dilapan
Study: NCT03630874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate the impact of a prescription support tool
Description: From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy.~In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the right prescription of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided.
Study: NCT01936584

Intervention type: PROCEDURE
Intervention: TAPP repair for inguinal hernias

Intervention type: PROCEDURE
Intervention: TEP repair for inguinal hernia

Intervention type: OTHER
Intervention: EuraHS-QoL questionnaire
Description: questionnaire administration

Intervention type: OTHER
Intervention: EuraHS-QoL questionnaire
Description: questionnaire administration

Intervention type: OTHER
Intervention: Carolina Comfort Scale
Description: questionnaire administration

Intervention type: OTHER
Intervention: Carolina Comfort Scale
Description: questionnaire administration
Study: NCT02065336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520